P1022 RANDOMIEZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS SPARING REGIMEN

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。对于在怀孕期间开始联合抗逆转录病毒治疗的女性来说，最佳策略尚不清楚。在怀孕期间开始抗逆转录病毒治疗的艾滋病毒感染妇女目前正在接受各种初始抗逆转录病毒疗法的治疗。来自ACTG 367的数据显示，到妊娠晚期，在怀孕期间开始抗逆转录病毒治疗的感染艾滋病毒的孕妇中，38%的人正在服用以酶抑制剂为基础的方案，其中奈非那韦是最常用的药物，15%的人正在服用含有3种药物的非酶抑制剂方案。随着时间的推移，接受奈韦拉平为基础的方案的妇女比例有所增加，从2000年7月到2001年2月，分娩的妇女比例达到了28%。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The optimal strategy is not known for women who initiate combination antiretroviral therapy during pregnancy. HIV-infected women who begin antiretroviral therapy during pregnancy are currently being treated with a variety of initial antiretroviral regimens. Data from ACTG 367 indicate that by the third trimester, 38% of HIV-invected pregnant women who initiate antiretroviral therapy during pregnancy are taking a protease inhibitor based regimen with nelfinavir as the most commen agent used and 15% are on a protease inhibitor-sparing regimen with 3 drugs. The proportion of women who received nevirapine-based regiments has increased over time, reaching 28% among deliveries from 7/00 to 2/01.